Center for Research in Security Prices, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Bryostatin 1 Plus Paclitaxel in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: bryostatin 1
Drug: paclitaxel

First Posted Date: 2004-04-26

Last Posted Date: 2013-02-11

Lead Sponsor: University of Chicago

Target Recruit Count: 15

Registration Number: NCT00005849

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States
🇺🇸
Michiana Hematology/Oncology P.C., South Bend, Indiana, United States

and more 7 locations

Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma

Phase 1

Completed

Conditions: Melanoma (Skin)

Interventions: Biological: MART-1 antigen
Biological: recombinant MAGE-3.1 antigen
Biological: recombinant interleukin-12

First Posted Date: 2004-04-22

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 20

Registration Number: NCT00002952

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

O6-benzylguanine and Carmustine in Treating Patients With Recurrent, Metastatic, or Locally Advanced Soft Tissue Sarcoma

Phase 2

Completed

Conditions: Sarcoma

Interventions: Drug: O6-benzylguanine
Drug: carmustine

First Posted Date: 2004-04-12

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 12

Registration Number: NCT00005066

Locations: 🇺🇸
Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States
🇺🇸
Division of Hematology/Oncology, Park Ridge, Illinois, United States
🇺🇸
Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States

and more 7 locations

Aminocamptothecin in Treating Patients With Stomach Cancer or Cancer of the Esophagus

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer

Interventions: Drug: aminocamptothecin

First Posted Date: 2004-03-30

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 15

Registration Number: NCT00003192

Locations: 🇺🇸
Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States
🇺🇸
Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States
🇺🇸
Oncology/Hematology Associates of Central Illinois, P.C., Peoria, Illinois, United States

and more 4 locations

A Comparison of Fluoxetine and Divalproex for the Treatment of Intermittent Explosive Disorder

Phase 2

Completed

Conditions: Intermittent Explosive Disorder

Interventions: Drug: Divalproex
Drug: Placebo
Drug: Fluoxetine

First Posted Date: 2004-03-08

Last Posted Date: 2021-04-27

Lead Sponsor: University of Chicago

Target Recruit Count: 90

Registration Number: NCT00078754

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: ZD1839

First Posted Date: 2004-02-27

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 51

Registration Number: NCT00015964

Locations: 🇺🇸
Evanston Northwestern Health Care, Evanston, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States

and more 8 locations

O6-benzylguanine Followed by Surgery in Treating Patients With Solid Tumors That Can Be Removed During Surgery

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: O6-benzylguanine

First Posted Date: 2004-02-20

Last Posted Date: 2014-03-06

Lead Sponsor: University of Chicago

Target Recruit Count: 25

Registration Number: NCT00003766

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Phase 2

Completed

Conditions: Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes

Interventions: Biological: anti-thymocyte globulin
Drug: cyclophosphamide
Drug: fludarabine phosphate
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2004-02-16

Last Posted Date: 2014-03-07

Lead Sponsor: University of Chicago

Target Recruit Count: 16

Registration Number: NCT00004145

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

Oxaliplatin in Treating Patients With Metastatic Bladder Cancer

Phase 2

Completed

Conditions: Bladder Cancer
Transitional Cell Cancer of the Renal Pelvis and Ureter

Interventions: Drug: oxaliplatin

First Posted Date: 2004-02-12

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 20

Registration Number: NCT00004203

Locations: 🇺🇸
Oncology/Hematology Associates of Central Illinois, P.C., Peoria, Illinois, United States
🇨🇦
Cancer Care Ontario-Hamilton Regional Cancer Centre, Hamilton, Ontario, Canada
🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States

and more 11 locations

SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: bicalutamide
Drug: flutamide
Drug: goserelin acetate
Drug: leuprolide acetate
Drug: SU5416
Radiation: radiation therapy

First Posted Date: 2004-02-06

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 3

Registration Number: NCT00026377

Locations: 🇺🇸
Radiation Oncology, Chicago, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
LaGrange Memorial Hospital, LaGrange, Illinois, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy